CTLA4 and melanoma: This discrepancy may be due to the different melanoma models that were used, differential effects of IFNGR1KO vs. IFNGR1KD in tumor cells, and/or different types of ICBs (anti-CTLA-4+anti-PD-L1 vs. anti-CTLA-4 alone), which warrants further investigations.